ALX Oncology (ALXO) Expected to Post Quarterly Earnings on Friday

ALX Oncology (NASDAQ:ALXO) is expected to be announcing its Q3 2026 resultson Friday, November 6th. Analysts expect ALX Oncology to post earnings of ($0.15) per share for the quarter. Parties can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 8:30 AM ET.

ALX Oncology (NASDAQ:ALXO) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01. On average, analysts expect ALX Oncology to post ($0.59) EPS for the current fiscal year and ($0.62) EPS for the next fiscal year.

ALX Oncology Price Performance

Shares of NASDAQ ALXO opened at $1.29 on Wednesday. The business has a 50 day simple moving average of $1.49 and a 200-day simple moving average of $1.82. ALX Oncology has a twelve month low of $0.86 and a twelve month high of $2.66. The company has a market capitalization of $178.38 million, a price-to-earnings ratio of -1.14 and a beta of 0.61. The company has a current ratio of 9.71, a quick ratio of 9.71 and a debt-to-equity ratio of 0.07.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of ALX Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 17th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $4.60.

About ALX Oncology

ALX Oncology Holdings Inc (NASDAQ: ALXO) is a clinical-stage biopharmaceutical company focused on developing immunotherapies for the treatment of cancer. The company’s research centers on the CD47-SIRPα pathway, an immune checkpoint that cancer cells can use to evade detection and destruction by the immune system.

ALX Oncology’s lead product candidate is evorpacept, also known as ALX148, an investigational protein designed to block CD47 while supporting the activity of therapeutic antibodies and other anti-cancer treatments.